Elite Pharmaceuticals, Inc. (ELTP)
|Net Income (ttm)||6.51M|
|Trading Day||April 15|
|Day's Range||0.0523 - 0.0569|
|52-Week Range||0.0480 - 0.0995|
NORTHVALE, NJ / ACCESSWIRE / January 5, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products...
Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets fo... [Read more...]
Drug Manufacturers-Specialty & Generic
|IPO Date |
Jul 23, 1998
|Stock Exchange |
|Ticker Symbol |
In 2019, ELTP's revenue was $17.99 million, an increase of 137.76% compared to the previous year's $7.57 million. Losses were -$2.24 million, -75.86% less than in 2018.